Abstract
The COVID-19 pandemic has created many challenges in the management of immune thrombocytopenic purpura (ITP). The recommendation for avoidance of steroids by WHO led to the off-licence use, supported by NHS England, of thrombopoietin mimetics (TPO-RA) for newly diagnosed or relapsed ITP. This is a real-world prospective study which investigated the treatment patterns and outcomes in this setting. Twenty-four hospitals across the UK submitted 343 cases. Corticosteroids remain the mainstay of ITP treatment, but TPO-RAs were more effective. Incidental COVID-19 infection was identified in a significant number of patients (9·5%), while 14 cases were thought to be secondary to COVID-19 vaccination.
Keywords: COVID; coronavirus disease 2019; immune thrombocytopenia; platelets; thrombocytopenia.
【저자키워드】 Coronavirus disease 2019, Platelets, COVID, thrombocytopenia, Immune thrombocytopenia, 【초록키워드】 Treatment, coronavirus disease, COVID-19 pandemic, hospital, Prospective Study, outcome, immune, COVID-19 vaccination, COVID-19 infection, management, Patient, Immune thrombocytopenic purpura, WHO, England, steroid, NHS, avoidance, effective, thought, investigated, diagnosed, supported, submitted, 【제목키워드】 COVID-19 pandemic, management, Immune thrombocytopenia,